Cite
HARVARD Citation
Fanale, D. et al. (2022). Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical reviews in oncology/hematology. p. . [Online].